MannKind Corporation to Participate in the BTIG Biotechnology Conference

Rhea-AI Summary

MannKind Corporation (Nasdaq: MNKD) announced its participation in the BTIG Biotechnology Conference on August 8-9, 2022. CEO Michael Castagna and CFO Steven Binder will engage in one-on-one meetings during this event, aimed at institutional investors.

BTIG specializes in various financial services and hosts client events across multiple sectors. MannKind is known for its innovative products for endocrine and lung diseases, notably Afrezza (insulin human) Inhalation Powder, the only inhaled ultra-rapid-acting insulin approved in the U.S. This participation highlights MannKind’s ongoing commitment to advancing its therapeutic portfolio.

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, and Chief Financial Officer, Steven Binder will participate in the BTIG Biotechnology Conference taking place on Monday, August 8 – Tuesday, August 9, 2022.

This conference is being hosted by BTIG, a global financial services firm specializing in institutional trading, investment banking, research, and related brokerage services. BTIG’s Corporate Access program hosts client events across the consumer, digital assets, energy and infrastructure, financials, healthcare, real estate, and technology sectors.

Management will be participating in one-on-one meetings throughout the event. To join the conference and arrange a meeting with management, please email info@btig.com.

About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of therapeutic and convenient products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza^® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. Afrezza is also available by prescription in Brazil, where it is commercialized by the Company’s partner, Biomm SA. MannKind was established in 1991, and is located in Danbury, Conn., and Westlake Village, Calif. The Company also employs field sales and medical representatives across the U.S. Please visit mannkindcorp.com to learn more.

Contact:
Rose Alinaya, Investor Relations
(818) 661-5000
Email: ir@mannkindcorp.com

FAQ

What is MannKind Corporation's participation in the BTIG Biotechnology Conference?

MannKind Corporation will participate in the BTIG Biotechnology Conference on August 8-9, 2022, with CEO Michael Castagna and CFO Steven Binder attending.

What are the dates of the BTIG Biotechnology Conference 2022?

The BTIG Biotechnology Conference is scheduled for August 8-9, 2022.

Who will represent MannKind Corporation at the BTIG Conference?

MannKind Corporation will be represented by CEO Michael Castagna and CFO Steven Binder at the conference.

What is Afrezza and its significance to MannKind Corporation?

Afrezza is MannKind Corporation's inhaled ultra-rapid-acting insulin, and it is the first FDA-approved inhaled insulin available in the U.S.

How can investors arrange meetings with MannKind's management during the conference?

Investors can arrange meetings with MannKind's management by emailing info@btig.com.